The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT03944109

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03944109
Other papers using this trial's data
  • PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study BMC medicine, 2022-01-18 DOI, PubMed 35039035, PMC8763618 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03944109. Randomized; triple masking; primary purpose treatment. Start 2019-06-20 (actual); primary completion 2020-12-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia
Condition
Hyperlipidemia
Intervention (Drug)
SHR-1209
Intervention (Drug)
Placebo
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03944109
Content hash
571385b91600e116219139258612d21c65ca4f6b8c379f00a9b0b0a370fec975